3Cambau E and Gutmann L. Mechanisms of resistance to quinolones. Drugs 1993; 45(suppl3): 15～23.
4Bebear CM, Charron A, Bove JM, et al.Cloning and nucleotide sequences of the topoisomerase Ⅳ parC and parE genes of Mycoplasma hominis. Antimicrobial Agents and Chemotherapy 1998; 42 (8): 2024～2031.
5Foumier B and Hooper DC. Efficts of mutations in GrlA of topoisomerase Ⅳ form Staphylococcus aureus on quinolone and coumarin activity. Antimicrobial Agents and Chemotherapy 1998; 42(8): 2109～2112.
6Mouneimne H, Robert J, Jarlier V, et al.Type Ⅱ Topoisomerase mutations in ciprofloxacin-resietant strains of pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 1999; 43 (1): 62～66.
7Weigel LM, Steward CD and Tenover FC. gyrA mutations associated with fluoroquinolone resistance in eight species of enterobacteriaceae.Anitmicrobial Agents and Chemotherapy 1998;42 ( 10): 2661 ～ 2667.
8Heisig P, Schedletzky H and Falkenstein-Paul H. Mutations in the gyrA gene of a highly fluoroquinolone-resistant clinical isolate of Escherichia coli. Antimicrobial Agents and Chemotherapy 1993;37 (4): 696～ 701.
9kumagai Y, Kato JI, Hoshino K, et al.Quinolone-resistant mutants of Escherichia coli DNA topoisomerase Ⅳ parC gene. Antimicrobial Agents and Chemotherapy 1996; 40 (3):710～714.
10Takenouchi T, Sakagawa E and Sugawara M.Detection of gyrA mutations among 335 Pseudomonas aeruginosa strains isolated in Japan and their susceptibilities to fluoroquinolones. Antimicrobial Agents and Chemotherapy 1999;43(2): 406～409.
